MLV reiterates its Buy rating and $4 target price on Zalicus ZLCS as a lawsuit settlement involving Exalgo allows company to market generic version six months in advance of plans.
MLV says, "In the settlement, Watson Pharmaceuticals will be permitted to launch certain dosage forms of a generic version of Exalgo in November 2013, just over 6 months ahead of patent expiry in July 2014. By that time, we do not expect an earlier generic launch will substantially impact Zalicus' collaboration revenue as
we expect the company will have new revenue generating agreements in place for its other drug candidates."
ZLCS closed at $1,15 a share on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in